IRIS
NAPOLITANO, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.856
AS - Asia 2.547
NA - Nord America 2.099
SA - Sud America 371
AF - Africa 35
OC - Oceania 3
Totale 11.911
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 5.016
US - Stati Uniti d'America 2.049
SG - Singapore 936
IE - Irlanda 598
IT - Italia 521
CN - Cina 516
HK - Hong Kong 486
BR - Brasile 321
DE - Germania 231
KR - Corea 182
VN - Vietnam 134
GB - Regno Unito 129
IN - India 83
JP - Giappone 67
UA - Ucraina 65
FR - Francia 61
SE - Svezia 46
FI - Finlandia 38
CA - Canada 31
GR - Grecia 31
PK - Pakistan 28
TR - Turchia 28
AT - Austria 26
NL - Olanda 20
AR - Argentina 19
BD - Bangladesh 19
CZ - Repubblica Ceca 17
BE - Belgio 14
PL - Polonia 14
ID - Indonesia 13
MX - Messico 13
ZA - Sudafrica 11
EC - Ecuador 10
AZ - Azerbaigian 9
ES - Italia 8
IQ - Iraq 8
MA - Marocco 7
PY - Paraguay 6
UZ - Uzbekistan 6
JO - Giordania 4
KE - Kenya 4
KG - Kirghizistan 4
KZ - Kazakistan 4
VE - Venezuela 4
DO - Repubblica Dominicana 3
IL - Israele 3
LT - Lituania 3
MK - Macedonia 3
PE - Perù 3
SA - Arabia Saudita 3
AE - Emirati Arabi Uniti 2
AO - Angola 2
AU - Australia 2
BO - Bolivia 2
CH - Svizzera 2
CL - Cile 2
CO - Colombia 2
EG - Egitto 2
GI - Gibilterra 2
IR - Iran 2
LK - Sri Lanka 2
SN - Senegal 2
TH - Thailandia 2
TN - Tunisia 2
TW - Taiwan 2
UY - Uruguay 2
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
DZ - Algeria 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IS - Islanda 1
MD - Moldavia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PT - Portogallo 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
Totale 11.911
Salva come PNG Salva come JPEG
Città #
Moscow 1.774
Dublin 584
Hong Kong 484
Singapore 447
Santa Clara 397
Chandler 282
Seoul 182
Naples 135
Hefei 109
Jacksonville 108
Dallas 99
Ashburn 98
New York 80
Beijing 78
Munich 69
Bremen 68
Princeton 66
Roxbury 66
Bengaluru 57
Ho Chi Minh City 53
The Dalles 53
Caserta 43
Los Angeles 38
Cambridge 37
Ann Arbor 33
São Paulo 31
Medford 29
Hanoi 25
Milan 22
Wilmington 20
Nuremberg 19
Brno 16
Elora 16
Boardman 14
Des Moines 14
Falkenstein 14
Brooklyn 13
Napoli 13
Tokyo 13
Vienna 13
Brussels 12
Warsaw 12
Woodbridge 12
Haiphong 11
Rome 11
San Francisco 11
Lappeenranta 10
Turku 10
Baku 9
Belo Horizonte 9
Houston 9
Istanbul 9
Rawalpindi 9
San Mateo 9
Amsterdam 8
Ercolano 8
London 8
Rio de Janeiro 8
Shanghai 8
Aversa 7
Columbus 7
Helsinki 7
Jinan 7
Tianjin 7
Dong Ket 6
Nanjing 6
Pozzuoli 6
Rimini 6
Tashkent 6
Toronto 6
Bahawalpur 5
Battipaglia 5
Brasília 5
Cape Town 5
Chennai 5
Chicago 5
Da Nang 5
Denver 5
Dhaka 5
Düsseldorf 5
Frosinone 5
Hải Dương 5
Jakarta 5
Johannesburg 5
Manchester 5
Menlo Park 5
Mercato San Severino 5
Mountain View 5
Seattle 5
Stockholm 5
Amman 4
Anantapur 4
Atlanta 4
Bari 4
Bishkek 4
Bologna 4
Boston 4
Campinas 4
Castellammare di Stabia 4
Council Bluffs 4
Totale 6.106
Salva come PNG Salva come JPEG
Nome #
Beyond N staging in colorectal cancer: Current approaches and future perspectives 196
AXL is an oncotarget in human colorectal cancer 172
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 165
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 164
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 164
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 158
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? 157
Immunotherapy for head and neck cancer: Present and future 149
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 149
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 147
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 144
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 144
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 144
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 140
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 138
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 138
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 138
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 137
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 136
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 134
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 134
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 134
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 134
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 133
Clinical management of metastatic colorectal cancer in the era of precision medicine 133
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 132
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 130
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 130
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 128
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 128
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 126
Post-Irradiation Breast Angiosarcoma: All the Possible Treatments and Electrochemotherapy. Case Report and Literature Review 124
"RT STRIKES BACK": Radiotherapy in Ultra Elderly with Cutaneous Basal Cell Carcinoma 124
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 124
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 124
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 124
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 123
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 122
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 121
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 121
Anti-EGFR-resistant clones decay exponentially after progression: Implications for anti-EGFR re-challenge 121
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 120
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 119
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 117
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 115
The Role of Adjuvant Therapy for the Treatment of Micrometastases in Endometrial Cancer: A Systematic Review and Meta-Analysis 114
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 114
Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma 113
Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment 113
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 112
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 112
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 110
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 110
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 109
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 108
Pimasertib hydrochloride 108
PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples 108
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 106
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 106
MET ACTIVATION BY AUTOCRINE LOOP RESCUES COLON CANCER CELLS FROM SENSITIVITY TO EGFR INHIBITION 105
It is finally time for adjuvant therapy in melanoma 105
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? 104
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 104
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 103
A retrospective observational study on cutaneous adverse events induced by immune checkpoint inhibitors 102
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation 102
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941 102
Prevention of cardiovascular complications in elderly cancer patients 101
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 101
Current Landscape and Open Questions on Adjuvant Therapies in Melanoma 101
Now or Later? The Role of Neoadjuvant Treatment in Advanced Endometrial Cancer: A Systematic Review 100
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer 100
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma 99
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial 98
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 98
Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis 96
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 96
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC 95
Treatment of cutaneous melanoma harboring smo p.Gln216arg mutation with imiquimod: An old drug with new results 95
The Role of Sentinel Node Biopsy in the Era of Adjuvant Therapy for Melanoma 94
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 93
Feasibility of next-generation sequencing in clinical practice: Results of a pilot study in the Department of Precision Medicine at the University of Campania ' Luigi Vanvitelli' 91
NMR profiling of Ononis diffusa identifies cytotoxic compounds against cetuximab-resistant colon cancer cell lines 91
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data 90
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines 89
Skin toxicity as predictor of survival in refractory patients with ras wild‐type metastatic colorectal cancer treated with cetuximab and avelumab (Cave) as rechallenge strategy 89
MicroRNA Expression in Endometrial Cancer: Current Knowledge and Therapeutic Implications 88
How we treat metastatic colorectal cancer 87
How we treat locoregional melanoma 86
Novel in vitro cancer models for optimizing anti- EGFR therapies 86
Predictive Evaluation on Cytological Sample of Metastatic Melanoma: The Role of BRAF Immunocytochemistry in the Molecular Era 85
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression 84
Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy 82
Mechanisms of innate and acquired resistance to anti-EGFR therapy: A review of current knowledge with a focus on rechallenge therapies 81
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments 81
Towards the era of precision medicine in metastatic colorectal cancer 78
Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer 78
Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer 77
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models 77
Obesity correlates to the microsatellite instability of endometrial cancer: A retrospective observational study 74
Totale 11.486
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.848
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.848
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021156 0 0 0 0 0 13 25 23 12 29 38 16
2021/2022514 15 13 6 4 105 15 38 15 30 59 64 150
2022/20231.193 127 18 32 96 149 97 5 66 545 9 33 16
2023/2024596 61 25 17 23 158 88 18 22 18 14 54 98
2024/20252.156 52 53 30 98 295 295 277 221 265 242 182 146
2025/20267.065 382 448 431 353 743 4.708 0 0 0 0 0 0
Totale 12.159